<DOC>
	<DOCNO>NCT00403494</DOCNO>
	<brief_summary>The purpose study evaluate whether 6R-BH4 ( sapropterin dihydrochloride ) safe effective treatment intermittent claudication ( IC ) cause peripheral arterial disease ( PAD ) .</brief_summary>
	<brief_title>A Phase 2 Study Effects 6R-BH4 Symptomatic Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>At least 40 year 80 year old A 6month ( long ) history walk limitation IC , severity change past 3 month Diagnosis PAD secondary atherosclerosis , PAD document Screening one follow criterion : 1 . Resting ABI &lt; 0.9 least one leg 2 . If rest ABI 0.91.0 , minimum postexercise drop ABI least 25 % least one leg 3 . If rest ABI &gt; 1.3 ( indicate noncompressible vessel ) , vascular etiology document toebrachial index ( TBI ) &lt; 0.7 least one leg On Gardner grade treadmill protocol , PWT least 1 minute , 12 minute Variation PWT two consecutive screening treadmill test less equal 25 % If currently receive treatment take following , willing able discontinue 30 day Screening throughout entire study ( include followup period ) : phosphodiesterase ( PDE ) 5 inhibitor ( eg , Viagra® , Cialis® , Levitra® , Revatio™ ) , PDE 3 inhibitor ( eg , cilostazol , milrinone , vesnarinone ) , pentoxifylline ( Trental® ) , nitrate , Larginine , ginkgo biloba , HeartBar For approximately 50 % subject enrol receive vitamin C study drug placebo , subject must willing discontinue take vitamin C supplement multivitamin contain vitamin C study . Antihypertensive therapy , cholesterollowering therapy ( eg , statin ) , diabetic therapy ( applicable ) stable 30 day prior Screening . Has change smoking exercise habit 30 day prior randomization unlikely study period Willing able provide write , sign informed consent nature study explain prior researchrelated procedure Willing able comply studyrelated procedure Sexually active subject must willing use acceptable method contraception participate study Females childbearing potential must negative pregnancy test Screening willing additional pregnancy test study Critical leg ischemia , manifest pain rest , ulceration , gangrene , leg amputation Surgical intervention alleviate symptom claudication ( eg , vascular reconstruction , sympathectomy ) within 6 month endovascular intervention cardiovascular surgery within 3 month Walking limited reason claudication ( eg , arthritis , lung disease , exerciselimiting cardiac disease , skin foot lesion limit walk ) Clinically significant ECG change exercise treadmill test Screening Baseline visit ( ) Myocardial infarction , deep vein thrombosis , cerebrovascular infarct within 3 month Screening Body mass index &gt; 40 ( gross obesity ) Hypertension Screening , define seat mean rest BP value &gt; 160 mmHg systolic , &gt; 110 mmHg diastolic , Hypotension Screening , define seat mean rest BP value &lt; 100 mmHg systolic &lt; 55 mmHg diastolic , clinically significant symptomatic ( orthostatic ) hypotension Nonatherosclerotic vascular disease ( eg , Buerger 's disease popliteal entrapment syndrome ) Previous treatment formulation BH4 Known allergy hypersensitivity excipient 6RBH4 Concurrent disease condition would interfere study participation safety bleed disorder , history severe gastrointestinal reflux disease , arrhythmia , organ transplant , organ failure , current neoplasm , type 1 diabetes mellitus , serious neurological disorder ( include seizure ) Previous treatment gene therapy vascular endothelial growth factor ( VEGF ) relate treatment Any severe comorbid condition would limit life expectancy le 6 month Serum creatinine &gt; 2.0 mg/dL hepatic enzyme level 2 time upper limit normal Concomitant treatment levodopa Requirement concomitant treatment drug know inhibit folate metabolism ( eg , methotrexate ) Use investigational product device within 30 day prior Screening , requirement investigational agent prior completion schedule study assessment Pregnant breastfeed Screening plan become pregnant ( subject partner ) time study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Intermittent Claudication</keyword>
	<keyword>IC</keyword>
	<keyword>Symptomatic Peripheral Arterial Disease</keyword>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>PAD</keyword>
	<keyword>6R-BH4</keyword>
	<keyword>BH4</keyword>
	<keyword>sapropterin dihydrochloride</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>NO</keyword>
</DOC>